Changes in Hong Kong stocks | True Healthcare-B (02697) rose more than 18% in early trading, overseas partners visited the company's core products one after another and CE certification for its core products is expected to be approved within the year

The Zhitong Finance App learned that True Healthcare-B (02697) surged more than 18% this morning. As of press release, it had risen 13.74% to HK$59.60, with a turnover of HK$56.3099 million.

According to the news, following the Brazilian partner's visit, the partner from Germany visited True Health Care on November 12 to conduct field visits and in-depth research. During this period, partners closely observed core products such as puncture surgery robots and microwave ablation surgery robots, and fully exchanged product technical principles, clinical advantages, and application scenarios. Currently, the company is speeding up its international strategic layout, and overseas registration work is progressing steadily. CE certification for core products is expected to be approved within the year, opening up a key entry channel for entering the EU and related accreditation system markets.

True Healthcare is the first high-end medical equipment company in China to simultaneously cover the three robotic technology routes of “piercing+ablation and organ preservation”. Up to now, the company has been approved with 10 Class III medical device registration certificates, 5 Class II medical device registration certificates, and applied for more than 350 intellectual property rights. The related products have entered more than 100 hospitals to carry out clinical work. They are used in the diagnosis and treatment of many thoracic and abdominal organs such as puncture biopsy, surgical positioning, precise ablation, particle implantation, etc., and completed more than 9,000 surgeries, with a 100% technical success rate, which is highly recognized by clinicians.